James Mwakyomo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Mwakyomo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Raphael Zozimus Sangeda
Sickle Cell Program, Department of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
10 shared publications - Prosper Njau
National AIDS, Sexually Transmitted Infections and Hepatitis Control Programme, Dodoma, Tanzania
8 shared publications Veryeh Sambu
National AIDS, Sexually Transmitted Infections and Hepatitis Control Programme, Dodoma, Tanzania
7 shared publications- Meshack D. Lugoba
Department of Pharmacognosy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
5 shared publications - Ritah Francis Mutagonda
Department of Clinical Pharmacy and Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
5 shared publications - Beatrice Mutayoba
National AIDS and Sexually Transmitted Infections Control Programme, Dodoma, Tanzania
4 shared publications
Latest Publications
- Open Access
Time to First-Line Antiretroviral Therapy Failure and Its Predictors among People Living with HIV in Tanzania
Introduction: Sustaining long-term viral suppression among people living with HIV (PLHIV) remains a major public health challenge in sub-Saharan Africa, despite widespread access to antiretroviral therapy (ART). Evidence on time to first-line ART failure and its predictors at a national scale remains limited, particularly for dolutegravir (DTG)-based regimens. We aimed to estimate the time to first-line ART failure and identify associated predictors among PLHIV in Tanzania using national programmatic data. Methods: We conducted a retrospective cohort study using routinely collected data from the National Care and Treatment Clinic database (CTC-2) in Tanzania. The analysis included PLHIV aged ≥11 years who initiated first-line ART between January 2017 and December 2021 and had at least six months of follow-up. Time to first-line ART failure was defined as the duration from ART initiation to the first documented virological failure (viral load ≥1,000 copies/mL). Kaplan-Meier methods were used to estimate failure-free survival, and Cox proportional hazards models were used to identify predictors of failure. Non-proportional hazards for DTG-based regimens were addressed using an extended Cox model with a time-varying coefficient. Results: The final analytic cohort comprised 36,764 individuals and 789 first-line treatment failure events. Median follow-up time varied across regimen groups. Failure-free survival differed significantly by regimen anchor (log-rank p<0.001). In multivariable Cox models, age and gender were significantly associated with treatment failure. DTG-based regimens demonstrated a time-varying effect: compared with non-DTG regimens, DTG was associated with a substantially lower hazard of failure early after initiation, with the protective effect attenuating over time. Estimated hazard ratios for DTG versus non-DTG regimens were 0.37, 0.67, and 1.22 at 6, 12, and 24 months of follow-up, respectively. Conclusions: In this large national cohort, the risk of first-line ART failure varied by regimen and patient characteristics. DTG-based regimens showed strong early protection against failure, but this effect diminished over time, highlighting the importance of continued virological monitoring after ART initiation. Time-to-event analyses using routine programmatic data provide important evidence for optimizing ART delivery and informing HIV programme decisions in Tanzania and similar settings.
Open AccessTime to First-Line Antiretroviral Therapy Failure and Its Predictors among People Living with HIV in Tanzania
Introduction: Sustaining long-term viral suppression among people living with HIV (PLHIV) remains a major public health challenge in sub-Saharan Africa, despite widespread access to antiretroviral therapy (ART). Evidence on time to first-line ART failure and its predictors at a national scale remains limited, particularly for dolutegravir (DTG)-based regimens. We aimed to estimate the time to first-line ART failure and identify associated predictors among PLHIV in Tanzania using national programmatic data. Methods: We conducted a retrospective cohort study using routinely collected data from the National Care and Treatment Clinic database (CTC-2) in Tanzania. The analysis included PLHIV aged ≥11 years who initiated first-line ART between January 2017 and December 2021 and had at least six months of follow-up. Time to first-line ART failure was defined as the duration from ART initiation to the first documented virological failure (viral load ≥1,000 copies/mL). Kaplan-Meier methods were used to estimate failure-free survival, and Cox proportional hazards models were used to identify predictors of failure. Non-proportional hazards for DTG-based regimens were addressed using an extended Cox model with a time-varying coefficient. Results: The final analytic cohort comprised 36,764 individuals and 789 first-line treatment failure events. Median follow-up time varied across regimen groups. Failure-free survival differed significantly by regimen anchor (log-rank p<0.001). In multivariable Cox models, age and gender were significantly associated with treatment failure. DTG-based regimens demonstrated a time-varying effect: compared with non-DTG regimens, DTG was associated with a substantially lower hazard of failure early after initiation, with the protective effect attenuating over time. Estimated hazard ratios for DTG versus non-DTG regimens were 0.37, 0.67, and 1.22 at 6, 12, and 24 months of follow-up, respectively. Conclusions: In this large national cohort, the risk of first-line ART failure varied by regimen and patient characteristics. DTG-based regimens showed strong early protection against failure, but this effect diminished over time, highlighting the importance of continued virological monitoring after ART initiation. Time-to-event analyses using routine programmatic data provide important evidence for optimizing ART delivery and informing HIV programme decisions in Tanzania and similar settings.
- Open Access
Uptake and predictors of viral load testing and viral suppression among people receiving antiretroviral therapy in mainland Tanzania
Background: Routine viral load monitoring is essential for assessing treatment effectiveness and for achieving global HIV treatment targets. Although viral load testing capacity has expanded across sub-Saharan Africa, gaps remain in monitoring coverage and equitable treatment outcomes. National-level analyses examining viral load uptake, suppression, and geographic variation in Tanzania remain limited. Methods: We conducted a retrospective observational analysis using routinely collected HIV programme data from the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP) Care and Treatment Clinic database. The analysis included 70,000 individuals receiving antiretroviral therapy between 2017 and 2021 across all regions of mainland Tanzania. Viral load uptake was defined as the presence of at least one documented viral load test during the observation period. Viral suppression was defined as a viral load result <1,000 copies/mL among individuals with available test results. Descriptive analyses summarized demographic and treatment characteristics, while multivariable logistic regression models identified predictors of viral load uptake and viral suppression. Geographic variation in programme performance was examined at regional and district levels using choropleth maps. Results: Among 70,000 individuals included in the analysis, 49,820 (71.2%) had at least one documented viral load result. Among those tested, 44,187 (88.7%) achieved viral suppression. Viral load uptake was lowest among young adults and slightly lower among males than females. Viral suppression was lower among children and adolescents than among older age groups. Individuals receiving dolutegravir-based regimens demonstrated higher viral suppression than those receiving NNRTI-based regimens. Substantial geographic heterogeneity was observed, with viral load uptake varying across regions and districts. Several districts characterized by mobile populations and seasonal migration patterns demonstrated comparatively lower monitoring coverage. Conclusions: Although viral load monitoring coverage and suppression levels among those tested were relatively high, important gaps remain in testing uptake and geographic equity. Adolescents, young adults, and populations in certain districts experience lower monitoring coverage and treatment outcomes. Strengthening viral load monitoring systems, expanding youth-responsive HIV services, and addressing geographic disparities will be important for sustaining progress toward national and global HIV treatment targets.
Open AccessUptake and predictors of viral load testing and viral suppression among people receiving antiretroviral therapy in mainland Tanzania
Background: Routine viral load monitoring is essential for assessing treatment effectiveness and for achieving global HIV treatment targets. Although viral load testing capacity has expanded across sub-Saharan Africa, gaps remain in monitoring coverage and equitable treatment outcomes. National-level analyses examining viral load uptake, suppression, and geographic variation in Tanzania remain limited. Methods: We conducted a retrospective observational analysis using routinely collected HIV programme data from the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP) Care and Treatment Clinic database. The analysis included 70,000 individuals receiving antiretroviral therapy between 2017 and 2021 across all regions of mainland Tanzania. Viral load uptake was defined as the presence of at least one documented viral load test during the observation period. Viral suppression was defined as a viral load result <1,000 copies/mL among individuals with available test results. Descriptive analyses summarized demographic and treatment characteristics, while multivariable logistic regression models identified predictors of viral load uptake and viral suppression. Geographic variation in programme performance was examined at regional and district levels using choropleth maps. Results: Among 70,000 individuals included in the analysis, 49,820 (71.2%) had at least one documented viral load result. Among those tested, 44,187 (88.7%) achieved viral suppression. Viral load uptake was lowest among young adults and slightly lower among males than females. Viral suppression was lower among children and adolescents than among older age groups. Individuals receiving dolutegravir-based regimens demonstrated higher viral suppression than those receiving NNRTI-based regimens. Substantial geographic heterogeneity was observed, with viral load uptake varying across regions and districts. Several districts characterized by mobile populations and seasonal migration patterns demonstrated comparatively lower monitoring coverage. Conclusions: Although viral load monitoring coverage and suppression levels among those tested were relatively high, important gaps remain in testing uptake and geographic equity. Adolescents, young adults, and populations in certain districts experience lower monitoring coverage and treatment outcomes. Strengthening viral load monitoring systems, expanding youth-responsive HIV services, and addressing geographic disparities will be important for sustaining progress toward national and global HIV treatment targets.
- Open Access
Time to registry discontinuity in Tanzania’s national HIV care registry: a survival analysis of population mobility patterns
Background: Early loss to follow-up (LTFU) after HIV enrolment is widely used to monitor program performance and progress toward treatment targets. These indicators assume that absence from the registering clinic reflects disengagement from care. However, in settings with substantial internal migration, patients may continue treatment at another facility while appearing to be lost in routine records. We evaluated the timing and geographic patterns of registry discontinuity following HIV registration in Tanzania to assess whether early LTFU primarily reflects patient disengagement from care or the characteristics of the monitoring system. Methods: We conducted a national registry-based observational analysis using routinely collected data from the HIV care registry maintained by the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP). The analysis included 2,136,207 individuals with recorded district registration and visit dates between 2017 and 2021. Registry discontinuity was defined as the interval between the first recorded visit and the absence of further recorded visits within the registration facility. Kaplan-Meier methods were used to estimate time-to-discontinuity patterns, and persistence curves were compared across predefined population mobility corridors (stable districts, urban migration districts, mining areas, pastoralist regions, and border districts). Threshold summaries were calculated at 30, 60, 90, and 180 days. Results: The median duration between the first and last recorded visits was 777 days (IQR, 217-1659). Registry discontinuity occurred predominantly soon after registration: 9.6% of individuals had no further recorded visits within 30 days, 11.8% within 60 days, 13.5% within 90 days, and 17.8% within 180 days of registration. A Kaplan-Meier analysis showed a steep early decline, followed by a prolonged plateau, indicating that most discontinuities occurred shortly after the first recorded visit. The time to registry discontinuity differed significantly across mobility corridors (log-rank p < 0.001), with earlier discontinuities in border, urban-migration, and mining districts compared with stable districts. Nearly one million individuals were recorded as newly registered in 2017, suggesting that first registry appearance frequently reflects administrative enrolment rather than first lifetime initiation of HIV care. Conclusions: Early registry discontinuity following HIV registration in Tanzania is common, occurring soon after the first recorded visit, and shows a consistent geographic structure associated with population mobility. These findings indicate that a substantial proportion of apparent early LTFU reflects administrative discontinuity rather than confirmed treatment interruption. Facility-based retention indicators may therefore underestimate treatment continuity among mobile populations. Monitoring systems capable of linking patient records across facilities and administrative boundaries are required to distinguish between geographic relocation and disengagement from care.
Open AccessTime to registry discontinuity in Tanzania’s national HIV care registry: a survival analysis of population mobility patterns
Background: Early loss to follow-up (LTFU) after HIV enrolment is widely used to monitor program performance and progress toward treatment targets. These indicators assume that absence from the registering clinic reflects disengagement from care. However, in settings with substantial internal migration, patients may continue treatment at another facility while appearing to be lost in routine records. We evaluated the timing and geographic patterns of registry discontinuity following HIV registration in Tanzania to assess whether early LTFU primarily reflects patient disengagement from care or the characteristics of the monitoring system. Methods: We conducted a national registry-based observational analysis using routinely collected data from the HIV care registry maintained by the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP). The analysis included 2,136,207 individuals with recorded district registration and visit dates between 2017 and 2021. Registry discontinuity was defined as the interval between the first recorded visit and the absence of further recorded visits within the registration facility. Kaplan-Meier methods were used to estimate time-to-discontinuity patterns, and persistence curves were compared across predefined population mobility corridors (stable districts, urban migration districts, mining areas, pastoralist regions, and border districts). Threshold summaries were calculated at 30, 60, 90, and 180 days. Results: The median duration between the first and last recorded visits was 777 days (IQR, 217-1659). Registry discontinuity occurred predominantly soon after registration: 9.6% of individuals had no further recorded visits within 30 days, 11.8% within 60 days, 13.5% within 90 days, and 17.8% within 180 days of registration. A Kaplan-Meier analysis showed a steep early decline, followed by a prolonged plateau, indicating that most discontinuities occurred shortly after the first recorded visit. The time to registry discontinuity differed significantly across mobility corridors (log-rank p < 0.001), with earlier discontinuities in border, urban-migration, and mining districts compared with stable districts. Nearly one million individuals were recorded as newly registered in 2017, suggesting that first registry appearance frequently reflects administrative enrolment rather than first lifetime initiation of HIV care. Conclusions: Early registry discontinuity following HIV registration in Tanzania is common, occurring soon after the first recorded visit, and shows a consistent geographic structure associated with population mobility. These findings indicate that a substantial proportion of apparent early LTFU reflects administrative discontinuity rather than confirmed treatment interruption. Facility-based retention indicators may therefore underestimate treatment continuity among mobile populations. Monitoring systems capable of linking patient records across facilities and administrative boundaries are required to distinguish between geographic relocation and disengagement from care.
- Open Access
Geographic variation in loss to follow-up from HIV care in Tanzania and its association with pharmacy refill adherence in routine programme data
Background: Sustained retention in HIV care is essential for achieving durable viral suppression and controlling the HIV epidemic. Loss to follow-up (LTFU) remains a persistent challenge in sub-Saharan Africa and shows substantial geographic variation. However, nationally representative analyses of routine monitoring data remain limited. Pharmacy refill data provide a scalable and objective approach for identifying individuals at risk of disengaging from care. We assessed the magnitude, spatial distribution, and predictors of LTFU among people living with HIV (PLHIV) receiving antiretroviral therapy (ART) across 26 mainland regions of Tanzania. Methods: We conducted a retrospective cohort analysis using routinely collected program data from the National Care and Treatment Clinic (CTC-2) database of PLHIV receiving ART in Tanzania between 2017 and 2021. LTFU was defined as no recorded clinic visit for ≥180 days after the last scheduled appointment, consistent with monitoring definitions used by the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP). Pharmacy refill adherence was calculated longitudinally and categorized as good (≥85%) or poor (<85%). Regional and district-level patterns were visualized using geospatial mapping. Multivariable logistic regression models were used to identify predictors of LTFU. Results: A total of 52,828 PLHIV were included in the study, representing all 26 mainland regions of Tanzania. Overall, 26.6% were classified as LTFU during follow-up, with marked regional variation. The highest proportional LTFU was observed in Dar es Salaam (33.2%), followed by Njombe (32.9%) and Geita (32.7%), while the lowest was recorded in Mwanza (19.1%) and Iringa (20.3%). Good pharmacy refill adherence (≥85%) was strongly associated with lower odds of LTFU and remained the most robust independent predictor after adjustment (adjusted odds ratio [aOR] 0.34; 95% confidence interval [CI] 0.32-0.35). District-level analyses revealed substantial within-region heterogeneity, identifying localized clusters of elevated attrition not apparent in regional aggregates. Conclusion: LTFU remains a major challenge to sustaining effective ART delivery in Tanzania. Pharmacy refill adherence may serve as a practical early indicator for identifying individuals at risk of disengagement from HIV care. Integrating refill-based monitoring with spatially informed analysis may support targeted retention strategies within routine HIV treatment programs.
Open AccessGeographic variation in loss to follow-up from HIV care in Tanzania and its association with pharmacy refill adherence in routine programme data
Background: Sustained retention in HIV care is essential for achieving durable viral suppression and controlling the HIV epidemic. Loss to follow-up (LTFU) remains a persistent challenge in sub-Saharan Africa and shows substantial geographic variation. However, nationally representative analyses of routine monitoring data remain limited. Pharmacy refill data provide a scalable and objective approach for identifying individuals at risk of disengaging from care. We assessed the magnitude, spatial distribution, and predictors of LTFU among people living with HIV (PLHIV) receiving antiretroviral therapy (ART) across 26 mainland regions of Tanzania. Methods: We conducted a retrospective cohort analysis using routinely collected program data from the National Care and Treatment Clinic (CTC-2) database of PLHIV receiving ART in Tanzania between 2017 and 2021. LTFU was defined as no recorded clinic visit for ≥180 days after the last scheduled appointment, consistent with monitoring definitions used by the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP). Pharmacy refill adherence was calculated longitudinally and categorized as good (≥85%) or poor (<85%). Regional and district-level patterns were visualized using geospatial mapping. Multivariable logistic regression models were used to identify predictors of LTFU. Results: A total of 52,828 PLHIV were included in the study, representing all 26 mainland regions of Tanzania. Overall, 26.6% were classified as LTFU during follow-up, with marked regional variation. The highest proportional LTFU was observed in Dar es Salaam (33.2%), followed by Njombe (32.9%) and Geita (32.7%), while the lowest was recorded in Mwanza (19.1%) and Iringa (20.3%). Good pharmacy refill adherence (≥85%) was strongly associated with lower odds of LTFU and remained the most robust independent predictor after adjustment (adjusted odds ratio [aOR] 0.34; 95% confidence interval [CI] 0.32-0.35). District-level analyses revealed substantial within-region heterogeneity, identifying localized clusters of elevated attrition not apparent in regional aggregates. Conclusion: LTFU remains a major challenge to sustaining effective ART delivery in Tanzania. Pharmacy refill adherence may serve as a practical early indicator for identifying individuals at risk of disengagement from HIV care. Integrating refill-based monitoring with spatially informed analysis may support targeted retention strategies within routine HIV treatment programs.
- Open Access
Predictors of loss to follow-up among patients receiving antiretroviral therapy in Njombe Region, Tanzania, 2017–2021
Background: Loss to follow-up (LTFU) undermines the success of antiretroviral therapy (ART) programs, especially in high HIV prevalence regions like Njombe, Tanzania. Understanding factors influencing LTFU is critical to enhance patient retention. Aim: To assess the prevalence and predictors of LTFU among people living with HIV (PLHIV) receiving ART in Njombe, Tanzania, from 2017 to 2021 Methods: We conducted a retrospective cohort study using the National Care and Treatment Clinic (CTC2) database, defining LTFU as absence from care for 180 days or more. Logistic regression identified factors associated with LTFU. Data were cleaned using Microsoft Excel and analyzed using IBM SPSS Statistics version 26. Descriptive statistics were used to summarize demographic and clinical characteristics, and logistic regression was used to identify independent predictors of LTFU Results: Of the 37,642 PLHIV initiated on ART, 13,411 (35.6%) were LTFU during the five-year study period. The highest annual incidence of LTFU occurred in 2020 (n = 4,069), coinciding with the onset of the COVID-19 pandemic. District-level disparities were substantial: Wanging’ombe recorded the highest disengagement prevalence (46.7%), while Makete recorded the lowest (23.7%). Multivariable analysis revealed that gender and age were not independent predictors of attrition (p > 0.05). However, significant associations with LTFU were observed for lower pharmacy refill adherence, marital status (single and divorced), and district of residence. Notably, patients in Wanging’ombe had more than double the odds of LTFU compared to those in Njombe (AOR 2.09; 95% CI: 1.95–2.24), whereas the 2021 initiation cohort demonstrated a significantly lower risk of disengagement (AOR 0.25; 95% CI: 0.22–0.28). Conclusion: LTFU remains a critical challenge in the Njombe Region. Targeted interventions, including strengthened pharmacy refill monitoring, district-specific strategies, and psychosocial support for PLHIV, are essential to improve retention and sustain progress toward national HIV treatment goals.
Open AccessPredictors of loss to follow-up among patients receiving antiretroviral therapy in Njombe Region, Tanzania, 2017–2021
Background: Loss to follow-up (LTFU) undermines the success of antiretroviral therapy (ART) programs, especially in high HIV prevalence regions like Njombe, Tanzania. Understanding factors influencing LTFU is critical to enhance patient retention. Aim: To assess the prevalence and predictors of LTFU among people living with HIV (PLHIV) receiving ART in Njombe, Tanzania, from 2017 to 2021 Methods: We conducted a retrospective cohort study using the National Care and Treatment Clinic (CTC2) database, defining LTFU as absence from care for 180 days or more. Logistic regression identified factors associated with LTFU. Data were cleaned using Microsoft Excel and analyzed using IBM SPSS Statistics version 26. Descriptive statistics were used to summarize demographic and clinical characteristics, and logistic regression was used to identify independent predictors of LTFU Results: Of the 37,642 PLHIV initiated on ART, 13,411 (35.6%) were LTFU during the five-year study period. The highest annual incidence of LTFU occurred in 2020 (n = 4,069), coinciding with the onset of the COVID-19 pandemic. District-level disparities were substantial: Wanging’ombe recorded the highest disengagement prevalence (46.7%), while Makete recorded the lowest (23.7%). Multivariable analysis revealed that gender and age were not independent predictors of attrition (p > 0.05). However, significant associations with LTFU were observed for lower pharmacy refill adherence, marital status (single and divorced), and district of residence. Notably, patients in Wanging’ombe had more than double the odds of LTFU compared to those in Njombe (AOR 2.09; 95% CI: 1.95–2.24), whereas the 2021 initiation cohort demonstrated a significantly lower risk of disengagement (AOR 0.25; 95% CI: 0.22–0.28). Conclusion: LTFU remains a critical challenge in the Njombe Region. Targeted interventions, including strengthened pharmacy refill monitoring, district-specific strategies, and psychosocial support for PLHIV, are essential to improve retention and sustain progress toward national HIV treatment goals.
- Open Access
Utilizing pharmacy refill data to predict loss to follow-up among people living with HIV in Manyara region of Tanzania
Background: Achieving optimal adherence and retention in HIV care is essential for sustaining viral suppression. Pharmacy refill records offer an objective approach to assessing adherence in settings where routine viral load testing is limited. This study evaluated pharmacy refill adherence, loss to follow-up (LTFU), and their predictors among people living with HIV (PLHIV) in the Manyara region of Tanzania. Methods: We conducted a retrospective cohort analysis of 22,650 PLHIV across five districts using the National CTC-2 database. LTFU was defined as no clinic visit for 180 days or more. We also analyzed a cross-sectional final status field updated by health trackers to distinguish research-defined LTFU from confirmed clinical outcomes. Predictors were evaluated using multivariable logistic regression, and spatial mapping identified geographic disparities. Results: The mean pharmacy refill adherence was 84.1%, with 57.9% achieving good adherence (>=85%). In the longitudinal analysis, 32.8% of patients met the research definition for LTFU (>=180-day absence) at some point during the study period. Cumulative LTFU was significantly higher in earlier initiation cohorts (2017-2019) compared to the 2021 cohort (aOR 1.89; 95% CI 1.76-2.02). However, cross-sectional system records, which health trackers update, showed that only 2.9% remained truly lost to care; 65.3% were active at their original clinic, 23.1% had eventually transferred to other facilities, and 6.7% were deceased. In multivariable regression, poor pharmacy adherence was the strongest behavioral predictor of disengagement (aOR 2.04; 95% CI 1.77-2.35). Significant geographic variation was observed, with residence in Simanjiro independently associated with the highest odds of LTFU (aOR 3.60; 95% CI 2.67-4.85). Spatial mapping confirmed a clustering of poor outcomes in districts characterized by nomadic pastoralist livelihoods. Conclusion: Pharmacy refill adherence is a potent predictor of disengagement and a practical early-warning indicator. The high rate of silent transfers and district-level disparities, particularly in nomadic hotspots, highlight the need for a national unique patient identifier and mobility-friendly retention strategies. Integrating automated refill alerts into the 90-day tracking window is essential to achieve 95-95-95 targets.
Open AccessUtilizing pharmacy refill data to predict loss to follow-up among people living with HIV in Manyara region of Tanzania
Background: Achieving optimal adherence and retention in HIV care is essential for sustaining viral suppression. Pharmacy refill records offer an objective approach to assessing adherence in settings where routine viral load testing is limited. This study evaluated pharmacy refill adherence, loss to follow-up (LTFU), and their predictors among people living with HIV (PLHIV) in the Manyara region of Tanzania. Methods: We conducted a retrospective cohort analysis of 22,650 PLHIV across five districts using the National CTC-2 database. LTFU was defined as no clinic visit for 180 days or more. We also analyzed a cross-sectional final status field updated by health trackers to distinguish research-defined LTFU from confirmed clinical outcomes. Predictors were evaluated using multivariable logistic regression, and spatial mapping identified geographic disparities. Results: The mean pharmacy refill adherence was 84.1%, with 57.9% achieving good adherence (>=85%). In the longitudinal analysis, 32.8% of patients met the research definition for LTFU (>=180-day absence) at some point during the study period. Cumulative LTFU was significantly higher in earlier initiation cohorts (2017-2019) compared to the 2021 cohort (aOR 1.89; 95% CI 1.76-2.02). However, cross-sectional system records, which health trackers update, showed that only 2.9% remained truly lost to care; 65.3% were active at their original clinic, 23.1% had eventually transferred to other facilities, and 6.7% were deceased. In multivariable regression, poor pharmacy adherence was the strongest behavioral predictor of disengagement (aOR 2.04; 95% CI 1.77-2.35). Significant geographic variation was observed, with residence in Simanjiro independently associated with the highest odds of LTFU (aOR 3.60; 95% CI 2.67-4.85). Spatial mapping confirmed a clustering of poor outcomes in districts characterized by nomadic pastoralist livelihoods. Conclusion: Pharmacy refill adherence is a potent predictor of disengagement and a practical early-warning indicator. The high rate of silent transfers and district-level disparities, particularly in nomadic hotspots, highlight the need for a national unique patient identifier and mobility-friendly retention strategies. Integrating automated refill alerts into the 90-day tracking window is essential to achieve 95-95-95 targets.
- Open Access
Leveraging Machine Learning Models and Pharmacy Refill Adherence as a Cost-Effective Proxy for Predicting HIV Viral Suppression during Antiretroviral Therapy in Resource-Limited Settings
Introduction: Achieving viral suppression is central to HIV epidemic control; however, routine viral load (VL) testing in many low- and middle-income countries is constrained by laboratory capacity, logistics, and cost. In Tanzania, disparities in VL coverage persist across age groups and geographical regions, limiting the timely detection of treatment failure. Pharmacy refill adherence is a low-cost, routinely collected objective indicator of treatment behavior. This study assessed whether pharmacy refill adherence, enhanced using machine learning (ML) models, can reliably predict viral suppression among people living with HIV (PLHIV) in Tanzania. Methods: We conducted a retrospective analysis using nationally representative patient-level data from the Care and Treatment Center (CTC-2) database, collected between 2017 and 2021. A random sample of 40,000 records was drawn, of which 28,044 patients met the inclusion criteria. Pharmacy refill adherence was calculated as the proportion of days covered and capped at 100%. Viral suppression was defined as a VL of 0.85), followed by Gradient Boosting Machines and Random Forest, while logistic regression provided stable baseline estimates. Pharmacy refill adherence, duration of follow-up, clinic visit frequency, and patient age were the strongest predictors of viral suppression. Conclusion: Pharmacy refill adherence is a strong predictor of viral suppression and provides a feasible and cost-effective tool for monitoring ART outcomes in settings with limited VL testing. Machine learning approaches further enhance the predictive value of routine program data and can support the early identification of patients at risk of virological failure. Integrating adherence-based predictive analytics into national HIV program monitoring systems may strengthen differentiated service delivery, improve treatment outcomes, and accelerate progress toward the UNAIDS 95–95–95 targets in Tanzania and similar resource-limited settings.
Open AccessLeveraging Machine Learning Models and Pharmacy Refill Adherence as a Cost-Effective Proxy for Predicting HIV Viral Suppression during Antiretroviral Therapy in Resource-Limited Settings
Introduction: Achieving viral suppression is central to HIV epidemic control; however, routine viral load (VL) testing in many low- and middle-income countries is constrained by laboratory capacity, logistics, and cost. In Tanzania, disparities in VL coverage persist across age groups and geographical regions, limiting the timely detection of treatment failure. Pharmacy refill adherence is a low-cost, routinely collected objective indicator of treatment behavior. This study assessed whether pharmacy refill adherence, enhanced using machine learning (ML) models, can reliably predict viral suppression among people living with HIV (PLHIV) in Tanzania. Methods: We conducted a retrospective analysis using nationally representative patient-level data from the Care and Treatment Center (CTC-2) database, collected between 2017 and 2021. A random sample of 40,000 records was drawn, of which 28,044 patients met the inclusion criteria. Pharmacy refill adherence was calculated as the proportion of days covered and capped at 100%. Viral suppression was defined as a VL of 0.85), followed by Gradient Boosting Machines and Random Forest, while logistic regression provided stable baseline estimates. Pharmacy refill adherence, duration of follow-up, clinic visit frequency, and patient age were the strongest predictors of viral suppression. Conclusion: Pharmacy refill adherence is a strong predictor of viral suppression and provides a feasible and cost-effective tool for monitoring ART outcomes in settings with limited VL testing. Machine learning approaches further enhance the predictive value of routine program data and can support the early identification of patients at risk of virological failure. Integrating adherence-based predictive analytics into national HIV program monitoring systems may strengthen differentiated service delivery, improve treatment outcomes, and accelerate progress toward the UNAIDS 95–95–95 targets in Tanzania and similar resource-limited settings.
- Open Access
Geospatial Quantification of Antiretroviral Therapy Consumption in Tanzania (2017-2021) Using the WHO Defined Daily Dose Methodology
Objectives: To quantify national and regional trends in antiretroviral therapy (ART) consumption in Tanzania from 2017 to 2021 using the World Health Organisation (WHO) Defined Daily Dose (DDD) methodology and to describe shifts in regimen composition during the transition to dolutegravir-based therapy. Methods: A retrospective descriptive analysis was conducted using programmatic dispensing data from the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP). ART dispensing records from all reporting HIV Care and Treatment Clinics were harmonised with WHO ATC/DDD codes and linked to annual population estimates. Consumption was expressed as DDDs per 1,000 inhabitants per day. Temporal trends, therapeutic class distributions, and regional variations were analysed using Power BI and R. Short-term national forecasts until 2025 were modelled using quadratic regression. Results: Between 2017 and 2021, ART consumption increased from 12.2 to 27.1 DDD/1,000/day (compound annual growth rate, 22.4%), with a five-year mean of 19.7 DDD/1,000/day. A total of 2,108,707 unique patients accounted for 39.7 million clinic visits in the study. The average number of visits per patient per year declined from 6.78 to 5.24, consistent with the expansion of the multi-month dispensing program (MM). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remained the core therapeutic class, whereas the use of integrase strand transfer inhibitors (INSTIs) has increased by more than tenfold since 2019. Dolutegravir (DTG) - based combinations (TDF/3TC/DTG) have become the predominant regimen, accounting for approximately 70% of dispensed DDDs by 2021. Regional variation narrowed over time, although the highest consumption persisted in Dar es Salaam, Mwanza, and Dodoma. Forecast modelling indicated continued moderate growth through 2025. Conclusions: The national ART consumption in Tanzania more than doubled between 2017 and 2021, reflecting the expansion of treatment coverage, evolution of differentiated service delivery, and the transition to DTG-based regimens. The routine computation of DDD per 1,000 inhabitants per day provides a standardised and feasible metric for monitoring ART utilisation within national HIV programs.
Open AccessGeospatial Quantification of Antiretroviral Therapy Consumption in Tanzania (2017-2021) Using the WHO Defined Daily Dose Methodology
Objectives: To quantify national and regional trends in antiretroviral therapy (ART) consumption in Tanzania from 2017 to 2021 using the World Health Organisation (WHO) Defined Daily Dose (DDD) methodology and to describe shifts in regimen composition during the transition to dolutegravir-based therapy. Methods: A retrospective descriptive analysis was conducted using programmatic dispensing data from the National AIDS and Sexually Transmitted Infections Control Programme (NASHCoP). ART dispensing records from all reporting HIV Care and Treatment Clinics were harmonised with WHO ATC/DDD codes and linked to annual population estimates. Consumption was expressed as DDDs per 1,000 inhabitants per day. Temporal trends, therapeutic class distributions, and regional variations were analysed using Power BI and R. Short-term national forecasts until 2025 were modelled using quadratic regression. Results: Between 2017 and 2021, ART consumption increased from 12.2 to 27.1 DDD/1,000/day (compound annual growth rate, 22.4%), with a five-year mean of 19.7 DDD/1,000/day. A total of 2,108,707 unique patients accounted for 39.7 million clinic visits in the study. The average number of visits per patient per year declined from 6.78 to 5.24, consistent with the expansion of the multi-month dispensing program (MM). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remained the core therapeutic class, whereas the use of integrase strand transfer inhibitors (INSTIs) has increased by more than tenfold since 2019. Dolutegravir (DTG) - based combinations (TDF/3TC/DTG) have become the predominant regimen, accounting for approximately 70% of dispensed DDDs by 2021. Regional variation narrowed over time, although the highest consumption persisted in Dar es Salaam, Mwanza, and Dodoma. Forecast modelling indicated continued moderate growth through 2025. Conclusions: The national ART consumption in Tanzania more than doubled between 2017 and 2021, reflecting the expansion of treatment coverage, evolution of differentiated service delivery, and the transition to DTG-based regimens. The routine computation of DDD per 1,000 inhabitants per day provides a standardised and feasible metric for monitoring ART utilisation within national HIV programs.
- Open Access
- 25 November 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5  (1)
Trends in antibiotic use among cardiovascular heart disease inpatients at the Jakaya Kikwete Cardiac Institute in Tanzania from 2016 to 2022
We assessed inpatient antibiotic use over six fiscal years at Tanzania’s national cardiac referral hospital. Overall use was 29.9 defined daily doses per 100 bed-days. Carbapenems were dominant. Reserve agents comprised 47.0%, and watch agents comprised 31.7%. Patterns indicate missed access targets and a need to strengthen stewardship in cardiac care.
- 25 November 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5  (1)
Open AccessTrends in antibiotic use among cardiovascular heart disease inpatients at the Jakaya Kikwete Cardiac Institute in Tanzania from 2016 to 2022
We assessed inpatient antibiotic use over six fiscal years at Tanzania’s national cardiac referral hospital. Overall use was 29.9 defined daily doses per 100 bed-days. Carbapenems were dominant. Reserve agents comprised 47.0%, and watch agents comprised 31.7%. Patterns indicate missed access targets and a need to strengthen stewardship in cardiac care.
- Open Access
Antibiotic Consumption Patterns among Outpatients at a Cardiac Tertiary Hospital in Tanzania
Background: Outpatient encounters are significant contributors to avoidable antibiotic exposure. However, the dispensing-based outpatient consumption data for Tanzania are limited. Most national estimates rely on import or sales data that do not reflect patient-level use. Cardiovascular clinics are particularly relevant because cardiopulmonary symptom overlap can lead to precautionary prescribing. Methods: We conducted a retrospective dispensing-based utilization analysis of cardiovascular outpatients at the Jakaya Kikwete Cardiac Institute (JKCI) in Dar es Salaam, Tanzania, from July 2017 to June 2022. Systemic antibacterial agents were mapped to the World Health Organization anatomical therapeutic chemical/defined daily dose (WHO ATC/DDD) and expressed as defined daily doses per 100 outpatients per day. Consumption patterns were summarized by fiscal year, molecule, ATC level 3, and WHO Access/Watch/Reserve (AWaRe) category. Monthly consumption was decomposed to evaluate trends and seasonality. Results: A total of 11,586 outpatients received at least one systemic antibiotic during the study period. Annual outpatient antibiotic utilization remained low and stable, ranging from approximately 0.27 to 0.38 DDD per 100 outpatients per day across fiscal years, with a cumulative total of 1.68 DDD per 100 outpatients per day across the five years. Consumption was dominated by beta-lactam/penicillin antibiotics, with Access antibiotics accounting for 48.5% of cumulative exposure, followed by Watch antibiotics (45.5%) and minimal Reserve use (5.9%). However, the Access proportion was below the WHO Access-60 benchmark for optimal outpatient use. Time-series decomposition revealed a modest upward trend, peaking in early 2021, accompanied by a recurring seasonal pattern of monthly use. Conclusion: Outpatient antibiotic utilization at JKCI was quantitatively low, yet showed persistent exposure dominated by Access antibiotics. Dispensing-based outpatient surveillance is feasible and should be integrated into routine stewardship dashboards to target avoidable outpatient antibiotic use.
Open AccessAntibiotic Consumption Patterns among Outpatients at a Cardiac Tertiary Hospital in Tanzania
Background: Outpatient encounters are significant contributors to avoidable antibiotic exposure. However, the dispensing-based outpatient consumption data for Tanzania are limited. Most national estimates rely on import or sales data that do not reflect patient-level use. Cardiovascular clinics are particularly relevant because cardiopulmonary symptom overlap can lead to precautionary prescribing. Methods: We conducted a retrospective dispensing-based utilization analysis of cardiovascular outpatients at the Jakaya Kikwete Cardiac Institute (JKCI) in Dar es Salaam, Tanzania, from July 2017 to June 2022. Systemic antibacterial agents were mapped to the World Health Organization anatomical therapeutic chemical/defined daily dose (WHO ATC/DDD) and expressed as defined daily doses per 100 outpatients per day. Consumption patterns were summarized by fiscal year, molecule, ATC level 3, and WHO Access/Watch/Reserve (AWaRe) category. Monthly consumption was decomposed to evaluate trends and seasonality. Results: A total of 11,586 outpatients received at least one systemic antibiotic during the study period. Annual outpatient antibiotic utilization remained low and stable, ranging from approximately 0.27 to 0.38 DDD per 100 outpatients per day across fiscal years, with a cumulative total of 1.68 DDD per 100 outpatients per day across the five years. Consumption was dominated by beta-lactam/penicillin antibiotics, with Access antibiotics accounting for 48.5% of cumulative exposure, followed by Watch antibiotics (45.5%) and minimal Reserve use (5.9%). However, the Access proportion was below the WHO Access-60 benchmark for optimal outpatient use. Time-series decomposition revealed a modest upward trend, peaking in early 2021, accompanied by a recurring seasonal pattern of monthly use. Conclusion: Outpatient antibiotic utilization at JKCI was quantitatively low, yet showed persistent exposure dominated by Access antibiotics. Dispensing-based outpatient surveillance is feasible and should be integrated into routine stewardship dashboards to target avoidable outpatient antibiotic use.